Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy.

The oncologist - 9 Mar 2026

Cai Jingshuang, Huang Zhiyang, Li Yingying, Zhou Jin, Xu Yingzhi, Cai Mingzhen, Zhao Hong, Zhao Bin

Abstract excerpt

BACKGROUND: The proto-oncogene rearranged during transfection (RET) mutation can influence tumor immunogenicity and regulate immune responses through multiple pathways. Herein, we performed an in-depth bioinformatic and clinical analysis to systematically evaluate the attributes of RET mutation and their interconnections with outcomes in pan-cancer immune checkpoint blockade (ICB) therapeutic interventions....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to RET gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Source

Open in PubMed Open full text

Identifiers

PMID: 41701164
DOI: 10.1093/oncolo/oyag049
PMCID: PMC12986760

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy.PMID 41701164Read ↗

RET mutation as a putative prognostic biomarker for immune checkpoint inhibitors therapy in various malignanciesSemantic proximity Read ↗

Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.Semantic proximity Read ↗

RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer.Semantic proximity Read ↗

65 YEARS OF THE DOUBLE HELIX: Exploiting insights on the RET receptor for personalized cancer medicineSemantic proximity Read ↗

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.Semantic proximity Read ↗

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Semantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.Semantic proximity Read ↗

REToma: a cancer subtype with a shared driver oncogene.Semantic proximity Read ↗

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.Semantic proximity Read ↗

Evaluation of NTRK3 mutation and a mutation-based gene set as biomarkers for immunotherapy outcomes in multiple cancersSemantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.